Form 8-K - Current report:
SEC Accession No. 0000899923-25-000072
Filing Date
2025-07-31
Accepted
2025-07-31 09:27:13
Documents
17
Period of Report
2025-07-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mygn-20250731.htm   iXBRL 8-K 37763
2 EX-10.1 ex101orbimed-myriadxcredit.htm EX-10.1 1103360
3 EX-10.2 ex102orbimed-myriadxpledge.htm EX-10.2 224517
4 EX-99.1 ex-991myriadgeneticsannoun.htm EX-99.1 10783
9 image.jpg GRAPHIC 33760
  Complete submission text file 0000899923-25-000072.txt   1775182

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mygn-20250731.xsd EX-101.SCH 2021
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mygn-20250731_def.xml EX-101.DEF 14426
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mygn-20250731_lab.xml EX-101.LAB 25279
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mygn-20250731_pre.xml EX-101.PRE 15012
19 EXTRACTED XBRL INSTANCE DOCUMENT mygn-20250731_htm.xml XML 2707
Mailing Address 322 NORTH 2200 WEST SALT LAKE CITY UT 84116
Business Address 322 NORTH 2200 WEST SALT LAKE CITY UT 84116 801-584-3600
MYRIAD GENETICS INC (Filer) CIK: 0000899923 (see all company filings)

EIN.: 870494517 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-26642 | Film No.: 251169835
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)